Free tool
FAERS Monitor: Immphentiv
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203826 or its brand name (Immphentiv, Phenylephrine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
3,598
Serious
3,445
96% of reports
Hospitalization
2,148
Death reported
1,812
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,363
- pemphigus1,074
- joint swelling1,038
- pain1,004
- maternal exposure during pregnancy1,003
- infusion related reaction996
- glossodynia995
- rheumatoid arthritis993
- drug ineffective984
- pericarditis983
- systemic lupus erythematosus981
- wound966
- synovitis963
- hepatic enzyme increased945
- folliculitis922
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 14 |
| 2006 | 6 |
| 2007 | 15 |
| 2008 | 15 |
| 2009 | 8 |
| 2010 | 43 |
| 2011 | 18 |
| 2012 | 52 |
| 2013 | 29 |
| 2014 | 16 |
| 2015 | 27 |
| 2016 | 28 |
| 2017 | 46 |
| 2018 | 46 |
| 2019 | 61 |
| 2020 | 109 |
| 2021 | 123 |
| 2022 | 267 |
| 2023 | 318 |
| 2024 | 976 |
| 2025 | 995 |
| 2026 | 384 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,561 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| folliculitisSignal | 922 | 563.4 | 531.1 | 471,891 |
| pemphigusSignal | 1,074 | 549.3 | 520.7 | 537,137 |
| pericarditisSignal | 983 | 363.2 | 343.6 | 334,269 |
| synovitisSignal | 963 | 329.7 | 311.7 | 298,717 |
| glossodyniaSignal | 995 | 271.9 | 257.4 | 256,607 |
| woundSignal | 966 | 209.2 | 198.0 | 193,325 |
| systemic lupus erythematosusSignal | 981 | 166.1 | 157.3 | 156,676 |
| infusion related reactionSignal | 996 | 89.2 | 84.5 | 85,702 |
| hepatic enzyme increasedSignal | 945 | 82.2 | 77.7 | 74,870 |
| maternal exposure during pregnancySignal | 1,003 | 66.5 | 63.1 | 64,212 |
| rheumatoid arthritisSignal | 993 | 51.6 | 48.9 | 49,028 |
| joint swellingSignal | 1,038 | 50.7 | 48.1 | 50,371 |
| painSignal | 1,004 | 9.6 | 9.1 | 7,914 |
| off label useSignal | 1,363 | 9.1 | 8.7 | 10,246 |
| drug ineffectiveSignal | 984 | 4.4 | 4.1 | 2,720 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.